Breastfeeding linked with decreased breast cancer recurrence risk
the ONA take:
According to a new Kaiser Permanente study published in the Journal of the National Cancer Institute, women diagnosed with breast cancer who previously breastfed their babies had a 30% overall decreased risk of disease recurrence.
For the study, researchers analyzed data from 1,636 women with breast cancer who completed a questionnaire that included breastfeeding history.
Researchers observed significant benefits between women who had a history of breastfeeding and outcomes of those diagnosed with the luminal A subtype of breast cancer, such as estrogen-receptor positive tumors. Results also showed women who breastfed were 28% less likely to die from the disease.
"Women who breastfeed are more likely to get the luminal A subtype of breast cancer, which is less aggressive, and breastfeeding may set up a molecular environment that makes the tumor more responsive to anti-estrogen therapy," lead author Marilyn L. Kwan, PhD said as a possible explanation of the observed association.
Women diagnosed with breast cancer who previously breastfed their babies had a 30% overall decreased risk of disease recurrence.
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic evaluation of obinutuzumab in combination with chlorambucil in first-line treatment of patients with chronic lymphocytic leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|